logo/base Created with Sketch.

Agile 4

Identification of cirrhosis in patients with MASLD

Agile 4 utilizes FibroScan®-based Biomarkers

chevron chevron

Agile 4 Target

Cirrhosis is a leading cause of mortality worldwide.

Identifying cirrhosis early in patients helps to proactively manage the disease through screenings for liver-related complications such as hepatocellular carcinoma and esophageal varices.

Discover Scores

Agile 4 Construction

Agile 4 combines LSM by VCTE® with easily accessible blood biomarkers (AST, ALT, Platelets) to help in the identification of cirrhosis in MASLD patients to properly identify patients to start HCC and portal hypertension screening.

Agile 4 Performance

High clinical performances demonstrated in large external validation cohorts from different geographical origins.

Clinical validation: Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with MASLD using FibroScanbased Agile scores, Journal of Hepatology, 2022.

Our liver health solutions

  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron

  • Agile 3+

    Identification of advanced fibrosis in MASLD patients.

    chevron

  • Fast

    Identification of at-risk MASH patients.

    chevron
  • FibroScan® Mini+ 430

    FibroScan® by echosens

    The non-invasive solution for comprehensive management of liver health

    chevron

Agile 4: tried and trusted

Agile 4 and Agile 3+ well predict the occurrence of liverrelated events in patients with MASLD. Particularly, rule-in cut-offs of both scores better identify at-risk patients than LSM alone. These results demonstrate the interest of those scores in the identification of patients requiring hepatocellular carcinoma and esophageal varices screening.

J. Boursier et all.

ILC 2021

A novel noninvasive score including LSM by VCTE and routine clinical parameters improves the identification of cirrhosis among patients with MASLD and may reduce the necessity of liver biopsy in this patient population.

AASLD 2020

Quote from AASLD 2020 poster conclusion

Discover the clinical evidence chevron

Request a demo!

Interested in FibroScan®?

Contact us
Agile 4 is a class I medical device according to Directive 93/42/EEC. Agile 4 calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of MASLD as having cirhhosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Agile 4 is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and health issues, it is not a substitute for or a replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.

*MASLD/MASH : formerly knowed as NAFLD/NASH

To access the Agile 4 User Guides, connect to myfibroscan.com:
Scores > Agile 4 > Learn more

chevron User Guides Agile 4